Ikena Oncology. has been granted a patent for anti-TREM1 antibodies, which are designed to enhance immune responses and treat immune-related conditions, including cancer. The patent details methods for using these antibodies to target non-stimulatory myeloid cells in patients. GlobalData’s report on Ikena Oncology gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Ikena Oncology, Cancer treatment biomarkers was a key innovation area identified from patents. Ikena Oncology's grant share as of July 2024 was 11%. Grant share is based on the ratio of number of grants to total number of patents.
Anti-trem1 antibodies for enhancing immune response in cancer
The granted patent US12065491B2 outlines a method for enhancing immune responses in subjects through the administration of isolated antibodies that specifically bind to TREM1. The antibodies are characterized by their variable heavy (VH) and light (VL) chain sequences, which include specific complementarity-determining regions (CDRs). The claims detail the sequences for these CDRs, including CDR-H1, CDR-H2, and CDR-H3 for the heavy chain, and CDR-L1, CDR-L2, and CDR-L3 for the light chain, with specific sequences provided in the patent. Additionally, the patent specifies that the antibodies may be afucosylated or humanized, and can be used in conjunction with various forms of immunotherapy, such as checkpoint inhibitors and CAR-T cell therapy.
Furthermore, the patent includes claims related to the treatment of cancer using the same isolated antibodies that bind to TREM1. Similar to the immune response claims, the cancer treatment claims also specify the sequences for the VH and VL chains and their respective CDRs. The patent emphasizes the potential for these antibodies to be administered to subjects who have previously received or are currently receiving other immunotherapies, including anti-PD1, anti-PDL1, or anti-CTLA4 antibodies. The detailed sequences and structural characteristics of the antibodies aim to provide a foundation for developing targeted therapies that could enhance immune responses and improve cancer treatment outcomes.
To know more about GlobalData’s detailed insights on Ikena Oncology, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
